Targeting CD47 for cancer immunotherapyZhongxing Jiang, Yongping Song|Journal of Hematology & Oncology|2021Cited by 342
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Chuan Jin et al.|The Lancet Haematology|2019Cited by 248
Targeting macrophages in hematological malignancies: recent advances and future directionsWei Li, Yongping Song|Journal of Hematology & Oncology|2022Cited by 162
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphomaYuankai Shi, Xin Zhang, Yongping Song et al.|Journal of Hematology & Oncology|2020Cited by 50
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Bo Peng, Hang Su et al.|EBioMedicine|2020Cited by 41